Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04539041 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
A Phase 1 study of Progressive Supranuclear Palsy (PSP), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 12
- Study locations
NCT04539041 is a Phase 1 study of Progressive Supranuclear Palsy (PSP) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 59 participants, below the 608-participant average among 4 other Progressive Supranuclear Palsy (PSP) trials with a reported enrollment target (90% lower). The trial reports 12 study locations across 6 states.
The verdict
NCT04539041, a Phase 1 study of Progressive Supranuclear Palsy (PSP), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
Conditions Studied
Interventions
- DRUG placebo
- DRUG antisense oligonucleotide
Study Locations (12)
Other
- Novartis Investigative Site - Düsseldorf
- Novartis Investigative Site - Hanover
- Novartis Investigative Site - München
- Novartis Investigative Site - Tübingen
- Novartis Investigative Site - Ulm
- Novartis Investigative Site - Southampton
Quebec
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Montreal
California
- University of California San Diego - La Jolla
Minnesota
- Mayo Clinic Rochester - Rochester
Tennessee
- Vanderbilt University Medical CenterX - Nashville
North Rhine-Westphalia
- Novartis Investigative Site - Bonn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2021-02-16 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04539041
The ClinicalTrials.gov registry entry for NCT04539041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 4 other Progressive Supranuclear Palsy (PSP) trials with a reported enrollment target (90% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Progressive Supranuclear Palsy (PSP) appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT04539041 reports 12 study locations spanning 6 distinct geographic areas - top geographies include Other, Quebec, California.
Frequently Asked Questions
What is clinical trial NCT04539041 about?
NCT04539041 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy". This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
What is the current status of trial NCT04539041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2021-02-16. Estimated completion is 2024-10-17.
What conditions does trial NCT04539041 study?
This clinical trial studies the following conditions: Progressive Supranuclear Palsy (PSP).
What interventions are being tested in trial NCT04539041?
The interventions under investigation include: placebo (DRUG), antisense oligonucleotide (DRUG).
Who is sponsoring clinical trial NCT04539041?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04539041 being conducted?
This trial has 12 study locations across California, Minnesota, Tennessee, Quebec, North Rhine-Westphalia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Supranuclear Palsy (PSP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
COMPLETED · Phase 1
-
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
RECRUITING · Early Phase 1
-
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
RECRUITING
-
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.